White House seeks data on U.S. manufacturing of 86 essential medicines

The White House Office of Management and Budget has launched a review of domestic production for a list of 86 medicines deemed essential.

The request asks manufacturers to provide information on where these drugs are made in the United States and the capacity available.

The list includes common treatments such as aspirin and the blood-pressure agent vasopressin, highlighting concerns about supply chain resilience.

Officials say the data will help assess whether current manufacturing can meet national needs and may guide future policy or incentives.